Elaine Campbell is a retired executive and currently serves as an advisor and board member. In 2016 she un-retired to serve as the interim president of Innovative Medicines Canada. Her role prior to retirement was as president of AstraZeneca Canada Inc., part of AstraZeneca PLC, one of the world’s leading biopharmaceutical companies, from 2012-2015. Ms. Campbell has more than 25 years of experience in the pharmaceutical industry, in global and North American leadership roles in multiple therapeutic areas. Ms. Campbell was a senior vice-president with DuPont Pharma, a division of E.I. DuPont & Nemours in the US. During her tenure there, she held executive roles within the commercial functions in both the US and Canada. Currently she is a member of the Advisory Board for Chemical Engineering at U of T, is on the Finance and Audit Committee of MaRS Discovery District, and advises a number of small companies.
Ms. Campbell holds a bachelor of applied science in chemical engineering from the University of Toronto and an MBA in marketing from St. Joseph’s University in Philadelphia.